24 October 2022
EMA/785930/2022
Human Medicines Division

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 24-27 October 2022

Chair: Sabine Straus – Vice-Chair: Martin Huber

24 October 2022, 10:30 – 19:30, via teleconference

25 October 2022, 08:30 – 19:30, via teleconference

26 October 2022, 08:30 – 19:30, via teleconference

27 October 2022, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)

10 November 2022, 09:00 – 12:00, via teleconference

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006 Rev.1).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 24 – 27 October 2022. See November 2022 PRAC minutes (to be published post December 2022 PRAC meeting).

1.2. Agenda of the meeting on 24-27 October 2022

Action: For adoption

1.3. Minutes of the previous meeting on 26-29 September 2022

Action: For adoption

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

None

3.2. Ongoing procedures

None

3.3. Procedures for finalisation

3.3.1. Janus kinase (JAK) inhibitors[1]: abrocitinib - CIBINQO (CAP); baricitinib - OLUMIANT (CAP); filgotinib - JYSELECA (CAP); tofacitinib - XELJANZ (CAP); upadacitinib - RINVOQ (CAP) – EMEA/H/A-20/1517

Applicant(s): AbbVie Deutschland GmbH & Co. KG (Rinvoq), Eli Lilly Nederland B.V. (Olumiant), Galapagos N.V. (Jyseleca), Pfizer Europe MA EEIG (Cibinqo, Xeljanz)

PRAC Rapporteur: Ulla Wändel Liminga; PRAC Co-rapporteur(s): Liana Gross-Martirosyan (Olumiant, Xeljanz), Nikica Mirošević Skvrce (Cibinqo, Jyseleca, Rinvoq)

Scope: Review of the benefit-risk balance following notification by the European Commission (EC) of a referral under Article 20 of Regulation (EC) No 726/2004, based on pharmacovigilance data

Action: For adoption of a recommendation to CHMP

3.4. Re-examination procedures[2]

3.4.1. Amfepramone (NAP) - EMEA/H/A-31/1501

Applicant(s): Artegodan GmbH, Temmler Pharma GmbH

PRAC Rapporteur: Ulla Wändel Liminga; PRAC Co-rapporteur: Roxana Dondera

Scope: Request for re-examination under Article 32 of Directive 2001/83/EC of the benefit-risk balance following notification by Romania of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Action: For adoption of a recommendation to CMDh

3.5. Others

None

4. Signals assessment and prioritisation[3]

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Olaparib - LYNPARZA (CAP)

Applicant: AstraZeneca AB

[1] Indicated for the treatment of inflammatory disorders
[2] Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
[3] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

PRAC Rapporteur: Amelia Cupelli

Scope: Signal of hepatocellular damage and hepatitis (HLT)

Action: For adoption of PRAC recommendation

EPITT 19846 – New signal

Lead Member State(s): IT

4.1.2. Ceftriaxone (NAP)

Applicant(s): various

PRAC Rapporteur: To be appointed

Scope: Signal of risk of factor V inhibition

Action: For adoption of PRAC recommendation

EPITT 19853 – New signal

Lead Member State(s): LV

4.2. New signals detected from other sources

4.2.1. Propofol (NAP)

Applicant(s): various

PRAC Rapporteur: To be appointed

Scope: Signal of medication errors that could potentially lead to life-threatening/fatal cases

Action: For adoption of PRAC recommendation

EPITT 19851 – New signal

Lead Member State(s): NO

4.2.2. Voriconazole - VFEND (CAP); VORICONAZOLE ACCORD (CAP); VORICONAZOLE HIKMA (CAP); NAP

Applicant(s): Accord Healthcare S.L.U. (Voriconazole Accord), Hikma Farmaceutica (Portugal), S.A. (Voriconazole Hikma), Pfizer Europe MA EEIG (Vfend), various

PRAC Rapporteur: To be appointed

Scope: Signal of drug interaction with flucloxacillin leading to subtherapeutic voriconazole levels

Action: For adoption of PRAC recommendation

EPITT 19849 – New signal

Lead Member State(s): NL

4.3. Signals follow-up and prioritisation

4.3.1. Durvalumab - IMFINZI (CAP) - EMEA/H/C/004771/SDA/010

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Signal of myelitis transverse

Action: For adoption of PRAC recommendation

EPITT 19815 – Follow-up to June 2022

4.3.2. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/SDA/059.1

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Signal of heavy menstrual bleeding

Action: For adoption of PRAC recommendation

EPITT 19780 – Follow-up to June 2022

4.3.3. Ipilimumab - YERVOY (CAP) - EMEA/H/C/002213/SDA/045; nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/SDA/0047

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Signal of pure red cell aplasia and aplastic anaemia

Action: For adoption of PRAC recommendation

EPITT 19804 – Follow-up to June 2022

4.3.4. Tildrakizumab – ILUMETRI (CAP) - EMEA/H/C/004514/SDA/008

Applicant: Almirall S.A

PRAC Rapporteur: Adam Przybylkowski

Scope: Signal of herpes zoster

Action: For adoption of PRAC recommendation

EPITT 19801 - Follow-up to June 2022

4.3.5. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/SDA/053.1

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: David Olsen

Scope: Signal of heavy menstrual bleeding

Action: For adoption of PRAC recommendation

EPITT 19783 – Follow-up to June 2022

4.4. Variation procedure(s) resulting from signal evaluation

None

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Bardoxolone methyl - EMEA/H/C/005869, Orphan

Applicant: Reata Ireland Limited

Scope: Treatment of chronic kidney disease

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Dapagliflozin - EMEA/H/C/006006

Scope: Treatment of type 2 diabetes mellitus, heart failure and chronic kidney disease

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Daprodustat - EMEA/H/C/005746

Scope: Treatment of anaemia associated with chronic kidney disease (CKD) in adults

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. Filgrastim - EMEA/H/C/005888

Scope: Reduction in the duration of neutropenia and the incidence of febrile neutropenia, indicated for the mobilisation of peripheral blood progenitor cells and persistent neutropenia in patients with advanced HIV infection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.5. Gadopiclenol - EMEA/H/C/005626

Scope: For diagnostic purposes: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. Gadopiclenol - EMEA/H/C/006172

Scope: For diagnostic purposes: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.7. Pegunigalsidase alfa - EMEA/H/C/005618, Orphan

Applicant: Chiesi Farmaceutici S.p.A.

Scope: Treatment of Fabry disease

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. Sirolimus - EMEA/H/C/005896, Orphan

Applicant: Plusultra pharma GmbH, Hybrid

Scope: Treatment of angiofibroma associated with tuberous sclerosis complex

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.9. Sitagliptin, metformin hydrochloride - EMEA/H/C/005778

Scope: Treatment of type 2 diabetes mellitus

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.10. Sodium phenylbutyrate, ursodoxicoltaurine - EMEA/H/C/005901, Orphan

Applicant: Amylyx Pharmaceuticals EMEA B.V.

Scope: Treatment of amyotrophic lateral sclerosis (ALS)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.11. Spironolactone - EMEA/H/C/005535

Scope: Indicated for the management of refractory oedema

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.12. Tremelimumab - EMEA/H/C/006016, Orphan

Applicant: AstraZeneca AB

Scope: For use in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Afamelanotide - SCENESSE (CAP) - EMEA/H/C/002548/II/0042, Orphan

Applicant: Clinuvel Europe Limited

PRAC Rapporteur: Martin Huber

Scope: Submission of an updated RMP version 9.1 in order to update the 'allergy and hypersensitivity risk' from potential to identified, following reported cases of positive allergy test results, confirming the causal association between the allergies and afamelanotide

Action: For adoption of PRAC Assessment Report

5.2.2. Meningococcal group A, C, W135 and Y conjugate vaccine - MENVEO (CAP) - EMEA/H/C/001095/II/0112

Applicant: GSK Vaccines S.r.l

PRAC Rapporteur: Menno van der Elst

Scope: Submission of an updated RMP version 10 in order to remove several safety concerns

Action: For adoption of PRAC Assessment Report

5.2.3. Siltuximab - SYLVANT (CAP) - EMEA/H/C/003708/II/0038, Orphan

Applicant: EUSA Pharma (Netherlands) B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Submission of the report from study ACCELERATE (Advancing Castleman Care with an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients with Castleman Disease - NCT02817997 listed as an obligation in the Annex II of the product information. This is a study Report to cover the data collected for 100 patients over a 5 year period in the ACCELERATE Registry study to collect information or patients with Castleman's Disease who are candidates to receive Sylvant or are currently receiving treatment with Sylvant. The Annex II is updated accordingly

Action: For adoption of PRAC Assessment Report

5.3. Medicines in the post-authorisation phase – CHMP-led procedures

5.3.1. Albutrepenonacog alfa - IDELVION (CAP) - EMEA/H/C/003955/II/0059, Orphan

Applicant: CSL Behring GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update information and amend the frequencies of adverse drug reactions (ADRs) based on the final results from

study CSL654_3003 (listed as a category 3 study in the RMP): an open-label, multicentre, uncontrolled study to evaluate the safety, pharmacokinetics and clinical response of recombinant factor IX albumin fusion protein (rIX-FP) with regard to the prevention and treatment of bleeding in previously untreated patients (PUPs) with haemophilia B. The package leaflet is updated accordingly. The RMP (version 4.0) has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information and update the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. Brolucizumab - BEOVU (CAP) - EMEA/H/C/004913/II/0018

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Update of sections 4.2 and 5.1 of the SmPC in order to introduce an alternative posology regimen for wet AMD and update information based on modelling and simulation studies; the package leaflet is updated accordingly. The RMP version 9.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.3. Concentrate of proteolytic enzymes enriched in bromelain - NEXOBRID (CAP) - EMEA/H/C/002246/II/0057, Orphan

Applicant: MediWound Germany GmbH

PRAC Rapporteur: Martin Huber

Scope: Submission of the 24-months' CSR addendum of the MW2010-03-02 (DETECT) category 1 study; a multicentre, multinational, randomised, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to gel vehicle and compared to standard of care. The provision of the CSR addresses the post-authorisation measure ANX 001.7. An updated RMP version 8.0 was provided as part of the application

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Dapagliflozin - EDISTRIDE (CAP) - EMEA/H/C/004161/WS2299/0055; FORXIGA (CAP) - EMEA/H/C/002322/WS2299/0076

Applicant: AstraZeneca AB

PRAC Rapporteur: Mari Thorn

Scope: Extension of indication to include population with heart failure (HF) and low ventricular ejection fraction (LVEF) > 40% for Forxiga and its duplicate Edistride, based on final results from study D169CC00001 (DELIVER); The DELIVER study is a category 3, PASS listed in the dapagliflozin RMP to evaluate the potential risk of lower limb amputation; this was an international, multi-centre, parallel-group, event-driven, randomised, double-blind, placebo-controlled Phase III study in patients with HF and LVEF > 40%, evaluating the effect of dapagliflozin 10 mg compared with placebo, given once daily in addition to background therapy, including treatments to control co-morbidities, in reducing the

composite of cardiovascular (CV) death or an HF event (hospitalisation for HF or urgent HF visit). As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet are updated in accordance. Version 27 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Diroximel fumarate - VUMERITY (CAP) - EMEA/H/C/005437/II/0005

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Submission of the final report from study ALK8700-A301: a phase 3 open label study to evaluate the long-term safety and tolerability of ALKS 8700 in adults with relapsing remitting multiple sclerosis (RRMS) listed as a category 3 study in the RMP. This is a multicentre, open-label study to evaluate the long-term safety, tolerability, and treatment effect over time of diroximel fumarate (DRF) administered for up to 96 weeks in adult participants with RRMS. The RMP version 1.1 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.6. Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/II/0062

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy, based on the pivotal Study R668-EE-1774. This is an ongoing phase 3, randomised, double-blind, placebo-controlled, 3-part (A, B, C) safety and efficacy study with an initial 24-week treatment period in adults (≥18 years of age) and adolescents (≥12 to <18 years of age) with EoE, and which includes an extended treatment period to a total of 52 weeks. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.7. Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/II/0063

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of adults with moderate to severe prurigo nodularis (PN) who are candidates for systemic therapy, based on results from studies EFC16459 and EFC16460 (PRIME and PRIME2); these are two phase 3, 24-week, randomised, double-blind, placebo-controlled, multi-centre, parallel group studies undertaken to evaluate the efficacy and safety of dupilumab in patients 18 years of age and older with moderate to severe PN, who are inadequately controlled on topical prescription therapies or when those therapies are not advisable. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of the SmPC are updated. The package leaflet is updated in accordance.

Version 8.0 of the RMP has also been submitted. As part of this application, the MAH is also requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.8. Durvalumab - IMFINZI (CAP) - EMEA/H/C/004771/II/0045

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from Study D419CC00002 (HIMALAYA): a randomised, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and package leaflet. Version 6.1 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. Ebola Zaire vaccine (live, attenuated) - ERVEBO (CAP) - EMEA/H/C/004554/II/0025

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include the paediatric population from 1 year to less than 18 years of age based on final results from study V920-016 (PREVAC); this is a phase 2, randomised, double-blind, placebo-controlled study of 2 leading Ebola vaccine candidates (Ad26.ZEBOV/MVA-BN-Filo and V920) and 3 vaccine strategies (Ad26.ZEBOV/MVABN-Filo, 1-dose V920, and 2 dose V920) to evaluate immunogenicity and safety in healthy children and adolescents from 1 to 17 years of age and adults 18 years of age and older. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.3 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the Annex II and the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/II/0083/G

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Extension of indication to include a 50-µg booster dose of Spikevax bivalent Original/Omicron BA.1 in children (6 to < 12 years), based on interim results from study P204; this is a Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age. As a consequence, sections 2, 4.1,

4.2, 4.4, 4.8, 5.1 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.5 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes.
To update sections 4.8, 5.1, and 6.6 of the SmPC to include additional immunogenicity data for the paediatric population (6 to < 18 years) based on Real-World Safety studies

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. Human normal immunoglobulin - HYQVIA (CAP) - EMEA/H/C/002491/II/0078

Applicant: Baxalta Innovations GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Update of section 4.8 and 5.1 of the SmPC in order to update safety data in paediatric population based on final results from study 161504 (listed as a category 3 study in the RMP) – post-authorisation safety, tolerability and immunogenicity evaluation of HyQvia in pediatric subjects with primary immunodeficiency diseases. This is a paediatric interventional phase 4 study performed to acquire additional data on safety, tolerability and immunogenicity of HyQvia in pediatric (age two to <18 years) patients with primary immunodeficiency diseases (PIDD). In addition, the MAH is taking this opportunity to update Annex II-D of the PI following procedure EMEA/H/C/002491/II/0070/G. The RMP version 13.1 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. Lenalidomide - REVLIMID (CAP) - EMEA/H/C/000717/II/0123

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and product information (PI) documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan (PPP) across the 3 immunomodulatory imide drugs (IMiDs). These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones. The updated RMP version 38 was provided

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.13. Onasemnogene abeparvovec - ZOLGENSMA (CAP) - EMEA/H/C/004750/II/0033/G, Orphan

Applicant: Novartis Europharm Limited, ATMP[4]

PRAC Rapporteur: Ulla Wändel Liminga

[4] Advanced therapy medicinal product

Scope: Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to introduce additional guidance on liver function laboratory tests and monitoring before and after infusion and update information based on new safety information on the topic of acute liver failure (ALF) following two reports of fatal ALF. Update of sections 4.2 and 4.4 of the SmPC in order to provide additional guidance relevant to patient's overall health status prior to dosing and to strengthen the existing description and guidance on systemic immune response. Update of the section 4.4 of the SmPC in order to indicate prompt attention to thrombotic microangiopathy (TMA) and to reflect the risk of life-threatening or fatal outcomes. The package leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to update the Annex II

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.14. Parathyroid hormone - NATPAR (CAP) - EMEA/H/C/003861/II/0042, Orphan

Applicant: Takeda Pharmaceuticals International AG

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of the updated protocol from study SHP634-403 listed as a specific obligation in the Annex II of the product information with twice-daily (BID) as the proposed alternative dosing regimen to be evaluated. This is a randomised, 2-Arm, double-blind, phase 4 study to evaluate once daily (QD) versus twice daily (BID) administration of recombinant human parathyroid hormone (rhPTH[1-84]; NATPARA) for the treatment of adults with hypoparathyroidism (HPT). The Annex II and the RMP (submitted version 3.4) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Pomalidomide - IMNOVID (CAP) - EMEA/H/C/002682/II/0047, Orphan

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Monica Martínez Redondo

Scope: Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 immunomodulatory imide drugs (IMiDs). These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the pregnancy prevention plan (PPP) will not be impacted. The updated RMP version 16 was provided

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.16. Ponatinib - ICLUSIG (CAP) - EMEA/H/C/002695/II/0064, Orphan

Applicant: Incyte Biosciences Distribution B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Extension of indication to include treatment of newly diagnosed adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), either with Iclusig (ponatinib) in combination with chemotherapy, or with Iclusig (ponatinib) monotherapy after corticosteroid induction in patients not eligible to receive chemotherapy-based regimens, based on final results from studies AP24534-11-001 and INCB 84344-201. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 22 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.17. Remimazolam - BYFAVO (CAP) - EMEA/H/C/005246/X/0002

Applicant: Paion Deutschland GmbH

PRAC Rapporteur: Rhea Fitzgerald

Scope: Extension application to introduce a new pharmaceutical form associated with a new strength (50 mg powder for concentrate for solution for injection/infusion). The new presentation comes with a new indication to include the intravenous induction and maintenance of general anaesthesia (GA) in adults for Byfavo (remimazolam) 50 mg, based on final results from two pivotal trials: 1) study ONO-2745-05: a phase 2b/3, single-blind, randomised, parallel-group study assessing safety and efficacy in induction and maintenance of anaesthesia in American Society of Anesthesiologists (ASA) I/II patients (general surgery); 2) study CNS-7056-022: a phase 3, randomised, propofol controlled, parallel group, confirmatory single-blind efficacy and safety trial during induction and maintenance of anaesthesia in ASA III/IV patients. A new combined version of the SmPC, labelling and package leaflet solely for the 50 mg strength and the GA indication is provided accordingly. The RMP (version 1.1) is updated accordingly. Finally, the MAH also requested an extension of the market protection by one additional year

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/X/0044/G

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: Extension application to introduce a new pharmaceutical form associated with two new strengths (6 mg/6 mg granules in capsule for opening and 15 mg/16 mg granules in capsule for opening), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of children and adolescents aged one year or older with chronic heart failure with left ventricular systolic dysfunction, based on the results of Study PANORAMA-HF (CLCZ696B2319): a multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of sacubitril/valsartan followed by a 52-week randomised, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of sacubitril/valsartan compared with enalapril in paediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.2 of the SmPC are being updated and the package leaflet is updated accordingly. In addition, an updated RMP version 4.0 was provided as part of the application. Further, the MAH requested a one year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.19. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/X/0042/G

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: Extension application to introduce a new pharmaceutical form associated with two new strengths (6 mg/6 mg granules in capsule for opening and 15 mg/16 mg granules in capsule for opening), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of children and adolescents aged one year or older with chronic heart failure with left ventricular systolic dysfunction, based on the results of Study PANORAMA-HF (CLCZ696B2319); a multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of sacubitril/valsartan followed by a 52-week randomised, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of sacubitril/valsartan compared with enalapril in paediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.2 of the SmPC are being updated and the package leaflet is updated accordingly. In addition, an updated RMP version 4.0 was provided as part of the application. Further, the MAH requested a one year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Somapacitan - SOGROYA (CAP) - EMEA/H/C/005030/X/0006/G, Orphan

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Martin Huber

Scope: Extension application to add a new strength of 15 mg/1.5 mL solution for injection in pre-filled pen grouped with a type II variation C.I.6 to add a new indication 'Replacement of endogenous growth hormone (GH) in children and adolescents with growth failure due to growth hormone deficiency (GHD)', based on results from the completed main 52-week period of the confirmatory phase 3 trial (4263), supported with long-term data from the phase 2 trial (4172), up to week 208 completed. As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the package leaflet has been updated accordingly. A revised RMP version 3.0 was provided as part of the application

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. Thalidomide - THALIDOMIDE BMS (CAP) - EMEA/H/C/000823/II/0076

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and product information (PI) documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan (PPP) across the 3 immunomodulatory imide drugs (IMiDs).

These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones, and to make some editorial changes in the labelling. The updated RMP version 20 was provided

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Tildrakizumab - ILUMETRI (CAP) - EMEA/H/C/004514/II/0036

Applicant: Almirall S.A

PRAC Rapporteur: Adam Przybylkowski

Scope: To add the 100 mg solution for injection in pre-filled pen which is an integrated part of the primary packaging of the medicinal product. RMP (version 1.2) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Tixagevimab, cilgavimab - EVUSHELD (CAP) - EMEA/H/C/005788/II/0003

Applicant: AstraZeneca AB

PRAC Rapporteur: Kimmo Jaakkola

Scope: Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of the SmPC in order to change the posology recommendations in the pre-exposure prophylaxis indication based on study TACKLE (D8851C00001). The package leaflet is updated accordingly. The RMP (version 2) has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/X/0147

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Extension application to add a new strength of 5/5 µg (tozinameran, famtozinameran) for children between 5 to 11 years of age. The RMP (version 7.2) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Treosulfan - TRECONDI (CAP) - EMEA/H/C/004751/II/0012, Orphan

Applicant: medac Gesellschaft fur klinische Spezialpraparate mbH

PRAC Rapporteur: Julia Pallos

Scope: Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with regards to CYP3A4, CYP2C19 and P-gp including physiologically based pharmacokinetic (PBPK) modelling. Version 1.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Treosulfan - TRECONDI (CAP) - EMEA/H/C/004751/II/0014, Orphan

Applicant: medac Gesellschaft fur klinische Spezialpraparate mbH

PRAC Rapporteur: Julia Pallos

Scope: Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of study MC-FludT.16/NM; a randomised phase II interventional study aimed to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases.
Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M, a Phase II trial to describe the safety and efficacy of Treosulfan based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/II/0027

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Extension of indication to include treatment of moderately to severely active Crohn's disease in adult patients for RINVOQ, based on final results from three Phase III studies, two confirmatory placebo-controlled induction studies (Study M14 431/U-EXCEED/CD-1) and Study M14 433/U-EXCEL/CD-2) and a placebo-controlled maintenance/long-term extension study (Study M14-430/U-ENDURE/CD-3). M14-431 study is a Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy. M14-433 study is a Phase III, Multicenter, Randomised, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies. M14-430 study is an ongoing Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease Who Completed the Studies M14-431 or M14-433. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated in accordance. Version 11 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Apremilast - OTEZLA (CAP) - PSUSA/00010338/202203

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Monica Martínez Redondo

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.2. Avacopan - TAVNEOS (CAP) - PSUSA/00010967/202203

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.3. Avelumab - BAVENCIO (CAP) - PSUSA/00010635/202203

Applicant: Merck Europe B.V.

PRAC Rapporteur: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.4. Brolucizumab - BEOVU (CAP) - PSUSA/00010829/202204

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.5. Bupivacaine, meloxicam - ZYNRELEF (CAP) - PSUSA/00010880/202203

Applicant: Heron Therapeutics, B.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.6. Cabotegravir - VOCABRIA (CAP) - PSUSA/00010900/202203

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.7. Cangrelor - KENGREXAL (CAP) - PSUSA/00010360/202203

Applicant: Chiesi Farmaceutici S.p.A.

PRAC Rapporteur: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.8. Cenobamate - ONTOZRY (CAP) - PSUSA/00010921/202203

Applicant: Angelini S.p.A.

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.9. Ciclosporin[5] - IKERVIS (CAP); VERKAZIA (CAP) - PSUSA/00010362/202203

Applicant(s): Santen Oy

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.10. Cinacalcet - MIMPARA (CAP) - PSUSA/00000756/202202

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.11. Dabigatran - PRADAXA (CAP) - PSUSA/00000918/202203

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Anette Kirstine Stark

[5] Topical use only

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.12. Dupilumab - DUPIXENT (CAP) - PSUSA/00010645/202203

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.13. Duvelisib - COPIKTRA (CAP) - PSUSA/00010939/202203

Applicant: Secura Bio Limited

PRAC Rapporteur: Željana Margan Koletić

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.14. Ebola vaccine (rDNA[6], replication-incompetent) - MVABEA (CAP); ZABDENO (CAP) - PSUSA/00010857/202203

Applicant(s): Janssen-Cilag International N.V.

PRAC Rapporteur: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.15. Filgotinib - JYSELECA (CAP) - PSUSA/00010879/202203

Applicant: Galapagos N.V.

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.16. Ganirelix - ORGALUTRAN (CAP) - PSUSA/00001517/202202

Applicant: Organon N.V.

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

[6] Recombinant deoxyribonucleic acid

6.1.17. Idecabtagene vicleucel - ABECMA (CAP) - PSUSA/00010954/202203

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP[7]

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.18. Lapatinib - TYVERB (CAP) - PSUSA/00001829/202203 (with RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.19. Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202203

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.20. Mepolizumab - NUCALA (CAP) - PSUSA/00010456/202203

Applicant: GlaxoSmithKline Trading Services Limited

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.21. Mifamurtide - MEPACT (CAP) - PSUSA/00002059/202203

Applicant: Takeda France SAS

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.22. Mogamulizumab - POTELIGEO (CAP) - PSUSA/00010741/202203

Applicant: Kyowa Kirin Holdings B.V.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

[7] Advanced therapy medicinal product

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.23. Naldemedine - RIZMOIC (CAP) - PSUSA/00010753/202203

Applicant: Shionogi B.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.24. Niraparib - ZEJULA (CAP) - PSUSA/00010655/202203

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.25. Obiltoxaximab - OBILTOXAXIMAB SFL (CAP) - PSUSA/00010885/202203

Applicant: SFL Pharmaceuticals Deutschland GmbH

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.26. Ofatumumab - KESIMPTA (CAP) - PSUSA/00010927/202203

Applicant: Novartis Ireland Limited

PRAC Rapporteur: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.27. Ponesimod - PONVORY (CAP) - PSUSA/00010940/202203

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.28. Rilpivirine[8] - REKAMBYS (CAP) - PSUSA/00010901/202203

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.29. Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202203

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.30. Selinexor - NEXPOVIO (CAP) - PSUSA/00010926/202203

Applicant: Stemline Therapeutics B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.31. Selumetinib - KOSELUGO (CAP) - PSUSA/00010936/202204

Applicant: AstraZeneca AB

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.32. Siponimod - MAYZENT (CAP) - PSUSA/00010818/202203

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.33. Sodium zirconium cyclosilicate - LOKELMA (CAP) - PSUSA/00010675/202203

Applicant: AstraZeneca AB

PRAC Rapporteur: Kirsti Villikka

[8] Intramuscular use only

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.34. Solriamfetol - SUNOSI (CAP) - PSUSA/00010831/202203

Applicant: TMC Pharma (EU) Limited

PRAC Rapporteur: Julia Pallos

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.35. Tepotinib - TEPMETKO (CAP) - PSUSA/00010979/202203

Applicant: Merck Europe B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.36. Tildrakizumab - ILUMETRI (CAP) - PSUSA/00010720/202203

Applicant: Almirall S.A

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.37. Vandetanib - CAPRELSA (CAP) - PSUSA/00009327/202204

Applicant: Genzyme Europe BV

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.38. Velaglucerase alfa - VPRIV (CAP) - PSUSA/00003103/202202

Applicant: Takeda Pharmaceuticals International AG

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.39. Velmanase alfa - LAMZEDE (CAP) - PSUSA/00010677/202203

Applicant: Chiesi Farmaceutici S.p.A.

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

6.2.1. Travoprost - IZBA (CAP); TRAVATAN (CAP); NAP - PSUSA/00003011/202202

Applicant(s): Novartis Europharm Limited (Izba, Travatan), various

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only

6.3.1. Alprazolam (NAP) - PSUSA/00000109/202203

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.2. Amlodipine (NAP) - PSUSA/00000174/202203

Applicant(s): various

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.3. Amoxicillin (NAP) - PSUSA/00000187/202203

Applicant(s): various

PRAC Lead: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.4. Amoxicillin, clavulanate (NAP) - PSUSA/00000188/202203

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.5. Aprotinin (NAP) - PSUSA/00000230/202202

Applicant(s): various

PRAC Lead: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.6. Aviptadil, phentolamine mesilate (NAP) - PSUSA/00010814/202202

Applicant(s): various

PRAC Lead: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.7. Cabergoline (NAP) - PSUSA/00000477/202203

Applicant(s): various

PRAC Lead: Valentina Di Giovanni

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.8. Chloroprocaine hydrochloride (NAP) - PSUSA/00010078/202203

Applicant(s): various

PRAC Lead: Željana Margan Koletić

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.9. Clodronic acid (NAP); clodronic acid, lidocaine (NAP) - PSUSA/00010650/202202

Applicant(s): various

PRAC Lead: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.10. Diphtheria, tetanus, pertussis (acellular, component) vaccine (adsorbed) (NAP); diphtheria, tetanus, pertussis (acellular, component) vaccine (adsorbed) reduced antigens contents (NAP) - PSUSA/00001125/202203

Applicant(s): various

PRAC Lead: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.11. Eplerenone (NAP) - PSUSA/00001236/202203

Applicant(s): various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.12. Erythromycin[9] (NAP) - PSUSA/00010808/202203

Applicant(s): various

PRAC Lead: Ronan Grimes

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.13. Fexofenadine (NAP) - PSUSA/00001388/202203

Applicant(s): various

PRAC Lead: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.14. Fluticasone propionate (NAP) - PSUSA/00001454/202202

Applicant(s): various

PRAC Lead: Polona Golmajer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[9] For systemic use only

6.3.15. Frovatriptan (NAP) - PSUSA/00001484/202203

Applicant(s): various

PRAC Lead: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.16. Germanium (^{68}Ge) chloride, gallium (^{68}Ga) chloride (NAP) - PSUSA/00010364/202203

Applicant(s): various

PRAC Lead: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.17. Naratriptan (NAP) - PSUSA/00002126/202202

Applicant(s): various

PRAC Lead: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.18. Nicorandil (NAP) - PSUSA/00002152/202202

Applicant(s): various

PRAC Lead: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.19. Oxycodone (NAP) - PSUSA/00002254/202204

Applicant(s): various

PRAC Lead: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.20. Phleum pratense[10] [11] [12] (NAP) - PSUSA/00010475/202203

Applicant(s): various

PRAC Lead: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.21. Rocuronium (NAP) - PSUSA/00002656/202202

Applicant(s): various

PRAC Lead: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.22. Sodium iodide (^{131}I) (NAP) - PSUSA/00002753/202203

Applicant(s): various

PRAC Lead: Marcia Sofia Sanches de Castro Lopes Silva

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.23. Varicella vaccine (live) (NAP) - PSUSA/00010473/202203

Applicant(s): various

PRAC Lead: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.24. Zolmitriptan (NAP) - PSUSA/00003150/202203

Applicant(s): various

PRAC Lead: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[10] Allergen for therapy
[11] For oromucosal use only
[12] Medicinal product(s) authorised via mutually recognition procedure only

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Laronidase - ALDURAZYME (CAP) - EMEA/H/C/000477/LEG 056.1

Applicant: Genzyme Europe BV

PRAC Rapporteur: Nathalie Gault

Scope: MAH's response to LEG 056 [Detailed review of cases of hypersensitivity reactions, immunogenicity, infusion-site reaction, overdose, cases suggestive of overdose and use of laronidase by intrathecal route, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00010581/202107) adopted in December 2021] as per request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

6.4.2. Venetoclax - VENCLYXTO (CAP) - EMEA/H/C/004106/LEG 017

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Eva Jirsová

Scope: From II-0031: Commitment to provide targeted tumour lysis syndrome (TLS) assessment reports on a biannual basis (submitted annually within the PSUR, and 6 months after the PSUR submission in a separate report) through 2023, and annually thereafter, as per the RMP v8.0.
These biannual assessment reports ensure close monitoring of the important identified risk of TLS, and the evaluation of the impact of newly implemented risk minimisation measures for TLS, on adherence to both already existing and updated recommendation added to the SmPC, the impact of the DHPC distributed to hematologists, and the patient card

Action: For adoption of advice to CHMP

6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/II/0077

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Update of section 4.8 of the SmPC to include acute and delayed urticaria as an adverse reaction, with the frequency 'rare', as requested by the PRAC in the 13th Safety Summary Report (EMEA/H/C/005791/MEA/011.12) concluded in June 2022. The package leaflet is updated accordingly

Action: For adoption of PRAC Assessment Report

6.6. Expedited summary safety reviews[13]

6.6.1. Coronavirus (COVID-19) vaccine (inactivated, adjuvanted, adsorbed) - COVID-19 VACCINE (INACTIVATED, ADJUVANTED) VALNEVA (CAP) - EMEA/H/C/006019/MEA 009.2

Applicant: Valneva Austria GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Third expedited summary safety report (SSR) for covid-19 vaccine (inactivated, adjuvanted) Valneva during the coronavirus disease (COVID-19) pandemic

Action: For adoption of advice to CHMP

7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[14]

7.1.1. Avapritinib – AYVAKYT (CAP) - EMEA/H/C/PSA/S/0092

Applicant: Blueprint Medicines

PRAC Rapporteur: Menno van der Elst

Scope: Substantial amendment to an agreed protocol for study BLU-285-1406: an observational study evaluating safety and efficacy of avapritinib in the first line treatment of patients with Platelet derived Growth Factor Alpha D842V mutated gastrointestinal stromal tumor

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Chlormadinone acetate, ethinylestradiol (NAP) - EMEA/H/N/PSA/J/0072.2

Applicant: Gedeon Richter Plc

PRAC Rapporteur: Martin Huber

Scope: Protocol for a a case control study comparing levonorgestrel and chlormadinone acetate (CMA) to compare the venous thromboembolism (VTE) risk of combined oral contraceptives (COCs) containing CMA 2mg / ethinylestradiol (EE) 30 µg, compared to COCs containing levonorgestrel (LNG) 0.15mg, both combined with 30 µg ethinylestradiol (EE), as required in the outcome of the referral procedure under Article 31 of Directive 2001/83/EC on Combined hormonal contraceptives completed in January 2014 (EMEA/H/A-31/1356)]

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

[13] Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

[14] In accordance with Article 107n of Directive 2001/83/EC

7.1.3. Lenalidomide - REVLIMID - EMEA/H/C/PSA/S/0093

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Substantial amendment to a previously agreed protocol for a PASS (listed as a specific obligation in the Annex II of the product information): post-authorisation, non-interventional, retrospective, drug-utilisation study to describe the pattern of use of lenalidomide in patients with myelodysplastic syndromes (MDS)

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.4. Valproate[15] (NAP) - EMEA/H/N/PSP/J/0094.3

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: MAH's response to PSP/J/0094.2 [protocol for a joint retrospective study of multiple European data sources characterising neurodevelopmental disorders in children exposed in utero to valproate and/or other antiepileptic drugs with long-term follow-up] as per the request for supplementary information (RSI) adopted in April 2022

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[16]

7.2.1. Anifrolumab - SAPHNELO (CAP) - EMEA/H/C/004975/MEA 001

Applicant: AstraZeneca AB

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Protocol for study D3461R00028: a multiple database study of the use (and safety) of anifrolumab in women with SLE during pregnancy

Action: For adoption of advice to CHMP

7.2.2. Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/MEA 002.1

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of a revised protocol for study PS0038: a non-interventional cohort study on the safety of bimekizumab in patients with plaque psoriasis comparing the risk of safety outcomes of interest in bimekizumab exposed patients compared to patients exposed to other biologics

Action: For adoption of advice to CHMP

[15] Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

[16] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

7.2.3. Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/MEA 003.1

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of a revised protocol for study PS0036: bimekizumab pregnancy exposure and outcome registry - an OTIS autoimmune diseases in pregnancy study

Action: For adoption of advice to CHMP

7.2.4. Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/MEA 004.1

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of a revised protocol for study PS0037: an observational cohort study to evaluate bimekizumab exposure during pregnancy and monitor the safety of bimekizumab use in pregnancy

Action: For adoption of advice to CHMP

7.2.5. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - JCOVDEN (CAP) - EMEA/H/C/005737/MEA 010.2

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of a revised protocol for study VAC31518COV4001 (listed as category 3 study in the RMP): a post-authorisation, observational study to assess the safety of Ad26.COV2.S using health insurance claims and/or electronic health record (EHR) database(s) in the United States, including FDA feedback

Action: For adoption of advice to CHMP

7.2.6. Coronavirus (COVID-19) vaccine (recombinant, adjuvanted) - NUVAXOVID (CAP) - EMEA/H/C/005808/MEA 004.1

Applicant: Novavax CZ, a.s.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: MAH’s response to MEA 004 [protocol for study 2019nCoV-402: UK Post-Authorisation Safety Study Using the Clinical Practice Research Datalink (CPRD): A surveillance study to characterize the safety profile of Nuvaxovid in adults aged 18 years and older in the real-world setting using the UK CPRD] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.2.7. Drospirenone, estetrol - DROVELIS (CAP) - EMEA/H/C/005336/MEA 001.3

Applicant: Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 001.2 [protocol for an international active surveillance study (INAS-NEES): a prospective non-interventional comparative cohort observational study to characterize and compare the risks of estetrol/drospirenone with combined oral contraceptive-containing levonorgestrel (COC-LNG) in a study population that is representative of the actual users of these preparations. The main clinical outcome of interest is venous thromboembolism (VTE), specifically deep venous thrombosis (DVT) and pulmonary embolism (PE)] as per the request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.2.8. Drospirenone, estetrol - LYDISILKA (CAP) - EMEA/H/C/005382/MEA 001.3

Applicant: Estetra SRL

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 001.2 [protocol for an international active surveillance study (INAS-NEES): a prospective non-interventional comparative cohort observational study to characterize and compare the risks of estetrol/drospirenone with combined oral contraceptive-containing levonorgestrel (COC-LNG) in a study population that is representative of the actual users of these preparations. The main clinical outcome of interest is venous thromboembolism (VTE), specifically deep venous thrombosis (DVT) and pulmonary embolism (PE) [final study report expected in December 2029] (from initial opinion/marketing authorisation (MA))] as per the request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.2.9. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 066.1

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: MAH's response to MEA 066 [protocol for study mRNA-1273-P911: long-term outcomes of myocarditis following administration of Spikevax (COVID-19 vaccine mRNA)] as per request for supplementary information (RSI) adopted in July 2022

Action: For adoption of advice to CHMP

7.2.10. Inebilizumab - UPLIZNA (CAP) - EMEA/H/C/005818/MEA 001

Applicant: Horizon Therapeutics Ireland DAC

PRAC Rapporteur: Amelia Cupelli

Scope: Protocol for an observational pregnancy safety study in women with neuromyelitis optica spectrum disorder (NMOSD) exposed to Uplizna (ineblizumab)

Action: For adoption of advice to CHMP

7.2.11. Inebilizumab - UPLIZNA (CAP) - EMEA/H/C/005818/MEA 003

Applicant: Horizon Therapeutics Ireland DAC

PRAC Rapporteur: Amelia Cupelli

Scope: Protocol for a real-world observational study of outcomes for patients with neuromyelitis optica spectrum disorder (NMOSD) treated With inebilizumab in Europe

Action: For adoption of advice to CHMP

7.2.12. Inebilizumab - UPLIZNA (CAP) - EMEA/H/C/005818/MEA 004

Applicant: Horizon Therapeutics Ireland DAC

PRAC Rapporteur: Amelia Cupelli

Scope: Protocol for a safety study of patients with neuromyelitis optica spectrum disorder (NMOSD) patients receiving inebilizumab following closure of the open-label period (N-MOmentum LT)

Action: For adoption of advice to CHMP

7.2.13. Linaclotide - CONSTELLA (CAP) - EMEA/H/C/002490/MEA 009.6

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Martin Huber

Scope: MAH's response MEA 009.5 [substantial amendment to a protocol previously agreed for PASS EVM-18888: linaclotide safety study assessing the complications of diarrhoea and associated risk factors in selected European populations with irritable bowel syndrome with constipation (IBS-C) for Constella (linaclotilde) 290µg capsule (protocol version 10.0)] as per request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.2.14. Lonapegsomatropin - SKYTROFA (CAP) - EMEA/H/C/005367/MEA 001.1

Applicant: Ascendis Pharma Endocrinology Division A/S

PRAC Rapporteur: Martin Huber

Scope: MAH’s response to MEA 001 [protocol for study VV-SUB-056752: a prospective, non-interventional, long-term, safety study of patients treated with lonapegsomatropin to further characterize the potential long-term safety risks of lonapegsomatropin in patients treated with under real-world conditions in the post-marketing setting] as per request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.2.15. Ponesimod - PONVORY (CAP) - EMEA/H/C/005163/MEA 001.2

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Anette Kirstine Stark

Scope: MAH's response to MEA 001 [protocol for study PCSNSP004001 (listed as a category 3 study in the RMP): ponesimod pregnancy outcomes enhanced monitoring (POEM) - pregnancy outcomes programme utilising enhanced pharmacovigilance monitoring to evaluate the potential risk of reproductive and embryofetal toxicity in pregnant women exposed to ponesimod together with a statistical analysis plan (SAP)] as per the request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.2.16. Ponesimod - PONVORY (CAP) - EMEA/H/C/005163/MEA 004.2

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Anette Kirstine Stark

Scope: MAH's response to MEA 004.1 [protocol for study PCSNSP003693 (listed as a category 3 study in the RMP): a survey among healthcare professionals (neurologists treating patients with multiple sclerosis (MS) along with MS specialist nurses) in selected European countries to evaluate knowledge and behaviours required for the safe use of ponesimod] as per the request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.2.17. Rivaroxaban - XARELTO (CAP) - EMEA/H/C/000944/MEA 049.3

Applicant: Bayer AG

PRAC Rapporteur: Mari Thorn

Scope: MAH's response to MEA 049.2 and updated protocol of Xarelto Paediatric VTE PASS Drug Utilization Study: an observational, longitudinal, multi-source drug utilization safety study to evaluate the drug use patterns and safety of rivaroxaban oral suspension in children under two years with venous thromboembolism (study number 22195) as per supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)[17]

7.3.1. Valproate[18] (NAP) - EMEA/H/N/PSR/J/0036

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of results for: 'survey among HCP to assess knowledge of HCP and behaviour with regards to pregnancy prevention plan(PPP) as well as receipt/use of DHPC and educational materials' and for 'survey among patients to assess knowledge of the patients with regards to PPP as well as receipt/use of educational materials'

Action: For adoption of recommendation to CMDh (or request for supplementary

[17] In accordance with Article 107p-q of Directive 2001/83/EC
[18] Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

information (RSI)

7.4. Results of PASS non-imposed in the marketing authorisation(s)[19]

7.4.1. Flutemetamol (^{18}F) - VIZAMYL (CAP) - EMEA/H/C/002557/II/0029

Applicant: GE Healthcare AS

PRAC Rapporteur: Martin Huber

Scope: Submission of the final report from study (GE067-027) listed as a category 3 study in the RMP in addition to a comprehensive root-cause analysis on the contributing factors having an impact on reader performance as requested by PRAC. This is a non-interventional PASS to evaluate the effectiveness of VIZAMYL reader training in Europe. The RMP version 3.4 has also been submitted and updated to reflect the completion of study GE067-028, previously assessed in MEA 003.3

Action: For adoption of PRAC Assessment Report

7.4.2. Lopinavir, ritonavir - KALETRA (CAP) - EMEA/H/C/000368/II/0193

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nathalie Gault

Scope: Submission of the final report from study P19-106 listed as a category 3 study in the RMP. This is a European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) observational study assessing the safety and effectiveness of Kaletra oral solution in children aged 14 days to 2 years with human immunodeficiency virus 1 (HIV-1) infection in Europe. The RMP version 10.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.3. Tafamidis - VYNDAQEL (CAP) - EMEA/H/C/002294/II/0081, Orphan

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Update of section 5.1 of the SmPC in order to update information based on final results from study B3461029 listed as a Specific Obligation in the Annex II of the product information. This is a non-interventional PASS sub-study evaluating effects of tafamidis on disease progression in patients with non-Val30Met mutations and symptomatic neuropathy. Consequently, the MAH proposes a switch from marketing authorisation under exceptional circumstances to full marketing authorisation given the fulfilment of the SOB. The Annex II and package leaflet are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

Action: For adoption of PRAC Assessment Report

[19] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

7.4.4. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/II/0091

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of the final safety registry report from study CNTO1275PSO4007: pregnancy research initiative - exposure to ustekinumab during pregnancy: a review and analysis of birth outcomes from the Swedish, Danish, and Finnish medical birth registers (in fulfilment of MEA 024). The RMP (version 22.1) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.5. Vortioxetine - BRINTELLIX (CAP) - EMEA/H/C/002717/II/0037

Applicant: H. Lundbeck A/S

PRAC Rapporteur: Jo Robays

Scope: Submission of the final report from study PASS 16034N listed as a category 3 study in the RMP. This is a non-interventional PASS of vortioxetine in Europe - An analysis of European automated healthcare databases. The RMP version 4.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

7.5.1. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/MEA 069

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: Interim report for study IM101816: a nationwide post-marketing study (PMS) on the safety of abatacept treatment in Sweden using the ARTIS Register

Action: For adoption of advice to CHMP

7.5.2. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/MEA 070

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: Interim report for study IM101803: a nationwide post-marketing study (PMS) on the safety of abatacept treatment in Denmark using the ARTIS Register

Action: For adoption of advice to CHMP

7.5.3. Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/SOB 009

Applicant: Blueprint Medicines (Netherlands) B.V.

PRAC Rapporteur: Menno van der Elst

Scope: First progress report for study BLU-285-1406 is an imposed non-interventional PASS aiming to confirm the safety and efficacy of avapritinib in the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the PDGFRA D842V mutation, given as Specific Obligation 3 (SOB3) of the Conditional Marketing Authorisation for AYVAKYT.
The submission of the first progress report is in line with agreed milestones in the Final PASS Protocol Assessment Report from the Pharmacovigilance Risk Assessment Committee (procedure number EMEA/H/C/PSP/S/0089.1 issued on 10 June 2021)

Action: For adoption of advice to CHMP

7.5.4. Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/004480/ANX 002.4

Applicant: Kite Pharma EU B.V., ATMP[20]

PRAC Rapporteur: Anette Kirstine Stark

Scope: Second interim report for study KT-EU-471-0117: a long-term, non-interventional study of recipients of Yescarta for treatment of relapsed or refractory Diffuse Large B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma. (EU PAS Register no.: EUPAS32539)

Action: For adoption of advice to CAT and CHMP

7.5.5. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 006.7

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: First annual report for study D8110C00003 (C-VIPER): COVID-19 Vaccines International Pregnancy Registry of Women Exposed to AZD1222 Immediately Before or During Pregnancy (Period covered 01/06/2021-31/05/2022) and MAH's response for MEA 006.5

Action: For adoption of advice to CHMP

7.5.6. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 003.7

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Sixth interim report for a study (listed as a category 3 study in the RMP): a post authorisation safety of Spikevax (elasomeran) in the US - an enhanced pharmacovigilance study to provide additional evaluation of adverse events of special interest (AESI) and emerging validated safety signals [P903]

Action: For adoption of advice to CHMP

[20] Advanced therapy medicinal product

7.5.7. Filgrastim - FILGRASTIM HEXAL (CAP) - EMEA/H/C/000918/MEA 007.13

Applicant: Hexal AG

PRAC Rapporteur: Menno van der Elst

Scope: MAH's response to MEA 007.12 [Eleventh annual report for study EP06-501 (SMART): a non-interventional, prospective, long-term safety data collection of Zarzio/Filgrastim Hexal (filgrastim) in healthy unrelated stem cell donors undergoing peripheral blood progenitor cell (PBPC) mobilisation] as per request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.5.8. Filgrastim - ZARZIO (CAP) - EMEA/H/C/000917/MEA 007.13

Applicant: Sandoz GmbH

PRAC Rapporteur: Menno van der Elst

Scope: MAH's response to MEA 007.12 Response to MEA-007.12 [Eleventh annual report for study EP06-501 (SMART): a non-interventional, prospective, long-term safety data collection of Zarzio/Filgrastim Hexal (filgrastim) in healthy unrelated stem cell donors undergoing peripheral blood progenitor cell (PBPC) mobilisation] as per request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.5.9. Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/MEA 006.3

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Interim report for study ALN-AS1-006: a global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP). [ELEVATE]

Action: For adoption of advice to CHMP

7.5.10. Ofatumumab - KESIMPTA (CAP) - EMEA/H/C/005410/MEA 003.1

Applicant: Novartis Ireland Limited

PRAC Rapporteur: Amelia Cupelli

Scope: MAH's response to MEA 003 [First annual interim report for COMB157G2399 (ALITHIOS) study (listed as a category 3 study in the RMP): an open-label, single arm, multicentre extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis] as per request for supplementary information (RSI) as adopted in June 2022

Action: For adoption of advice to CHMP

7.5.11. Selexipag - UPTRAVI (CAP) - EMEA/H/C/003774/MEA 001.8

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Nathalie Gault

Scope: MAH's response to MEA 001.7 [fifth annual interim report for PASS AC-065A401 (EXPOSURE): an observational cohort study of pulmonary arterial hypertension (PAH) patients newly treated with either Uptravi (selexipag) or any other PAH-specific therapy in routine clinical practice] as per request for supplementary information (RSI) adopted in June 2022

Action: For adoption of advice to CHMP

7.6. Others

7.6.1. Ulipristal acetate - ESMYA (CAP) - EMEA/H/C/002041/MEA 028.3

Applicant: Gedeon Richter Plc.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: MAH's request for cancelling the study PGL18-001: a retrospective drug utilisation study (DUS) through a chart review across four major EU countries [final study report expected by Q2 2020], as requested in the outcome of the referral procedure under Article 20 of Regulation (EC) No 726/2004 completed in May 2018 (EMEA/H/A-20/1460)]

Action: For adoption of advice to CHMP

7.7. New Scientific Advice

7.7.1.

7.8. Ongoing Scientific Advice

None

7.9. Final Scientific Advice (Reports and Scientific Advice letters)

None

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Lomitapide - LOJUXTA (CAP) - EMEA/H/C/002578/S/0052 (without RMP)

Applicant: Amryt Pharmaceuticals DAC

PRAC Rapporteur: Menno van der Elst

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.2. Nelarabine - ATRIANCE (CAP) - EMEA/H/C/000752/S/0058 (without RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.3. Smallpox vaccine (live modified vaccinia virus Ankara) - IMVANEX (CAP) - EMEA/H/C/002596/S/0077 (without RMP)

Applicant: Bavarian Nordic A/S

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.4. Vestronidase alfa - MEPSEVII (CAP) - EMEA/H/C/004438/S/0032 (without RMP)

Applicant: Ultragenyx Germany GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.2. Conditional renewals of the marketing authorisation

8.2.1. (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-

azabicyclo[3.1.0]hexane-2-carboxamide, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/R/0023 (without RMP)

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Martin Huber

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.2. Bedaquiline - SIRTURO (CAP) - EMEA/H/C/002614/R/0050 (without RMP)

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3. Renewals of the marketing authorisation

8.3.1. Bictegravir, emtricitabine, enofovir alafenamide - BIKTARVY (CAP) - EMEA/H/C/004449/R/0052 (without RMP)

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.2. Darvadstrocel - ALOFISEL (CAP) - EMEA/H/C/004258/R/0036 (with RMP)

Applicant: Takeda Pharma A/S, ATMP[21]

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CAT and CHMP

8.3.3. Dolutegravir, rilpivirine - JULUCA (CAP) - EMEA/H/C/004427/R/0049 (without RMP)

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Nathalie Gault

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

[21] Advanced therapy medicinal product

8.3.4. Ex vivo expanded autologous human corneal epithelial cells containing stem cells - HOLOCLAR (CAP) - EMEA/H/C/002450/R/0048 (without RMP)

Applicant: Holostem Terapie Avanzate s.r.l., ATMP[22]

PRAC Rapporteur: Rhea Fitzgerald

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CAT and CHMP

8.3.5. Fulvestrant - FULVESTRANT MYLAN (CAP) - EMEA/H/C/004649/R/0016 (without RMP)

Applicant: Mylan Pharmaceuticals Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.6. Glibenclamide - AMGLIDIA (CAP) - EMEA/H/C/004379/R/0014 (without RMP)

Applicant: Ammtek

PRAC Rapporteur: Maria del Pilar Rayon

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.7. Prasugrel - PRASUGREL MYLAN (CAP) - EMEA/H/C/004644/R/0014 (without RMP)

Applicant: Mylan Pharmaceuticals Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.8. Trastuzumab - KANJINTI (CAP) - EMEA/H/C/004361/R/0022 (without RMP)

Applicant: Amgen Europe B.V., BREDA

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.9. Velmanase alfa - LAMZEDE (CAP) - EMEA/H/C/003922/R/0029 (without RMP)

Applicant: Chiesi Farmaceutici S.p.A.

[22] Advanced therapy medicinal product

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States' safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

11.1.1. Ifosfamide (NAP) - SE/H/xxxx/WS/585

Applicant(s): Baxter Medical AB (Holoxan[23])

PRAC Lead: Ulla Wändel Liminga

Scope: PRAC consultation on a worksharing variation procedure (SE/H/xxxx/WS/585) for ifosfamide-containing medicinal products on the applicability of the conclusions of the referral procedure under Article 31 of Directive 2001/83/EC for ifosfamide-containing solutions (EMEA/H/A-31/1495) and on the product information wording on central nervous system (CNS) toxicity warnings including the associated risk factors, following the recommendation of PSUR single assessment (PSUSA) procedure (PSUSA/00001723/202007) concluded in March 2021, on request of Sweden

Action: For adoption of advice to Member States

11.1.2. Levonorgestrel[24] (NAP) - SE/H/xxxx/WS/582

Applicant(s): Bayer AB

PRAC Lead: Ulla Wändel Liminga

Scope: PRAC consultation on a worksharing variation procedure (SE/H/xxxx/WS/582) for levonorestrel-containing medicinal products to address the onset of contraceptive efficacy as well as the product information wording to further minimise the risk of insertion after conception, related to the recommendation of PSUR single assessment (PSUSA) procedure (PSUSA/00010828/202105) concluded in January 2022, on request of Sweden

Action: For adoption of advice to Member States

11.2. Other requests

None

[23] Ifosfamide powder for solution for injection
[24] All indications except emergency contraception

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. Coronavirus (COVID-19) pandemic - summary safety reports (SSRs) timetables

Action: For adoption

12.1.2. PRAC membership

Action: For information

12.1.3. PRAC Training for Assessors 2022 – course overview

Action: For discussion

12.1.4. PRAC working group - Best practice guide on using PRAC plenary time efficiently and effectively – update on the implementation of quantitative goals – Q3 2022

Action: For discussion

12.1.5. Vote by proxy

None

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Coronavirus (COVID-19) pandemic - update

Action: For discussion

12.5. Cooperation with International Regulators

None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

12.7.1. PRAC work plan 2023

PRAC lead: Sabine Straus, Martin Huber

Action: For discussion

12.8. Planning and reporting

12.8.1. European Commission (EC) report on performance of pharmacovigilance tasks - third three-yearly report

Action: For discussion

12.8.2. EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q3 2022 and predictions

Action: For discussion

12.8.3. PRAC workload statistics – Q3 2022

Action: For discussion

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Periodic safety update reports

None

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Menno van der Elst, Maia Uusküla

Action: For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

Action: For adoption

12.11. Signal management

12.11.1. Signal management – feedback from Signal Management Review Technical (SMART) Working Group

PRAC lead: Menno van der Elst

Action: For discussion

12.12. Adverse drug reactions reporting and additional reporting

12.12.1. Management and reporting of adverse reactions to medicinal products

None

12.12.2. Additional monitoring

None

12.12.3. List of products under additional monitoring – consultation on the draft list

Action: For adoption

12.13. EudraVigilance database

12.13.1. Activities related to the confirmation of full functionality

None

12.13.2. EudraVigilance: change to L2A downloads

Action: For adoption

12.14. Risk management plans and effectiveness of risk minimisations

12.14.1. Risk management systems

None

12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.14.3. Good Pharmacovigilance Practice (GVP) module V - Revision 3 update

Action: For discussion

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies – imposed PASS

None

12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

None

12.21. Others

12.21.1. Public consultation on a. Good Practice Guide for the use of the EU metadata catalogue and b. Data Quality Framework

Action: For discussion

12.21.2. Good Pharmacovigilance Practice (GVP) – end-of-year update for 2022 and planning for 2023

PRAC lead: Sabine Straus

Action: For discussion

13. Any other business

14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures

(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation

(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)

(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)

(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)

(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections

(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/